Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
corporate icon
XCell® ATF Devices and Controllers
XCell® ATF Systems simplify and fast-track upstream intensification by providing an integrated solution consisting of an XCell® ATF Device, XCell® ATF Controller, software, tubing, pressure sensors and accessories. The family of Systems supports diverse applications across development from 1L to 5000 L.
external link icon
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing
news icon
Repligen completes the acquisition of Metenova
Repligen acquired Metenova, a leading Swedish innovator in magnetic mixing technology for biopharmaceutical production. This strategic step further strengthens Repligen's Fluid Management franchise, enriching our single-use mixing solutions and expanding our product range. Welcome, Metenova!
external link icon
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 million Fourth quarter orders and revenues sequentially increased 11% and 8% respectively Orders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024. The company is also providing financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13% excluding COVID, overcoming two points of currency headwind. Total orders outpaced sales by 6%,
external link icon
Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT
external link icon
Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging
external link icon
Repligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST
external link icon
Repligen Announces Conference Call of Second Quarter Fiscal Year 2010 Results Thursday, November 5th, 10:00 a.m. EST
external link icon
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results Thursday, February 5th, 10:00 a.m. EST
corporate icon
Modalities
​A NEW GENERATION OF BIOLOGICS New modalities, such as viral vectors and mRNA, are critical in addressing challenging targets in bioprocessing. In addition to mAbs and rProteins, these exciting and potent clinical modalities promise faster, more efficient therapeutics with a broad range of potential applications.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support